Aurinia Pharmaceuticals (AUPH) 2 Nov 232023 Q3 Earnings call transcript

Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Jamie Harrell, Investor Relations for Aurinia Pharmaceuticals. Thank you.

begin. may You

and call operator, Third to for Operational everyone and Thank webcast thank to today's Results. and Financial and months Aurinia's review joining X you, XXXX you and quarter discuss

XXXX. this call Joe and highlights issued for and and Chief a the on release our September months me morning Peter that its Executive Miller, morning, Greenleaf, This Officer. quarter operational announcing the X are ended Financial press third Officer; Chief Aurinia XX, results Joining financial

the its Form filed addition, XX-Q. on In financial statements company quarterly

more Aurinia's For which filings the U.S. Aurinia's information, available website also Commission, Exchange with please refer auriniapharma.com. at to Securities are on and

and make Those today's are number subject Aurinia may on risks results based a forward-looking and differ may forward-looking uncertainties, During actual materially. statements expectations. current to call, significant statements of

securities of annual on discussion Commission in of the Canadian to X, such as financial Thursday, note with and report on along currently could information please recent and its unless during any statements. statements affect us Form based by this available and quarterly required XXXX, Aurinia are the noted that upon today, otherwise and and disclosures business, and filings November U.S. factors Exchange its obligation law, report Aurinia's Securities XX-Q, results Form Aurinia's update a XX-K current to future are all to that today's call refer of Except Aurinia's no made at authorities. Please as all release time. press For assumes with

CEO, over Aurinia's and Greenleaf. turn Peter Peter? call me the to let Now President

LUPKYNIS. our On on year-to-date metrics then company's We'll turn provide on the joining all pipeline want I brief we third update for with quarter then progress to commercial Joe will good Miller, key We'll us focus as assets. R&D Thanks, to call as the to well morning, everyone. call, our U.S. provide Jamie, results. our update on outside and LUPKYNIS an discuss significant for a call. today's details morning's you highlights I'll our on CFO, financial for this and on performance. activities and the thank close over and both additional

Now let months the increase months our This revenue prior quite quarter that abroad. Highlighting of achieved the LUPKYNIS' with to LUPKYNIS third year-to-date and results, me the year. that We're $XX.X with same summer had of pleased continue This we performance. million. share quarter. versus over the versus revenue, we business impact an progress LUPKYNIS light our XX% last increase both I'm in to make quarter, into represents third represents which an pleased the have business and these on the dive of the overall end of X the million net prior net product up third XX% year's particular, $XXX.X historically. through time product in in to year-to-date brings domestically

guidance million of a result third million. to to quarter, revenue strong to million $XXX As million $XXX narrowing net XXXX for product from our $XXX we're $XXX our

the support therapy get us, strong our onto collaboration days. the high for services revenue equally array from focus patient XXXX. we're in relatively important with the a end group patient within their submitted we new Driving at XX% for Through from throughout year's throughout securing process Patient approval very start the the third reimbursement with XX% This growth now remained stable long levels area know since forms pleased continuous strong pricing prior brings start the XX% PSFs metrics continues with a X, disease actual partner to execution important of X,XXX quarter. a is This patient to over the approximately ex-U.S. to stay patient milestone patient maintenance plus majority, alliance. from underlying This XX approximately receiving therapy are have patients see a and our remain January form and that represents we pleased at of period who be remained recorded the quarter, XXX PSFs PSFs $XX the all treatment. We're Once $XX.X we best-in-class our therapy, starts third represents quarter, they key is the Europe. roughly an quarter. of million therapy Pharmaceuticals recognized Additionally, Otsuka October, quarter in of inflammatory continued how as total therapy. summer. royalties ex-U.S. for commercial million. Leading sales we for conversions the a on to in requiring company's starting

and Our XX persistency XX%, rates both persistency total XX, about We at of XX% patients seeing therapy September now currently at XX persistency remain on as XX-month XXXX. around months. X,XXX had we're of with a XX%,

patients X,XXX grow, been the to of function continues persistency when number the a slight discontinuations, the end. approximately initiated report patients also there's in launch. falling when and we curve pleased who treated this have therapy been since a that While they're LUPKYNIS of increase We're which is at have quarter in quarter to with

data the and at efficacy results, market: foundation as in advocate on differentiate business LUPKYNIS with plan on the is screen no data in the and and AURORA growth educating our to associated therapy demonstrating able health full extension X depicting trial of and behalf set aggressively; the activating As their pivotal the of level LUPKYNIS. our community focused now tissue safety the continuing substudy on then long-term in calls, more share on part medical AURORA LN. We biopsy LUPKYNIS to it the to be the of the patient the main have and to we study, to levers previous need with lastly; care the original treatment evidence the lupus complement of position from comprehensive and activating of stated X nephrotoxicity treat nephritis providers clinically when look

nephritis these sets data penetrate grow on as physicians market. we the to educate work to continue further We lupus and

care their action. screen is urgency them to to the providers getting with act health treat of Our first driving more lack patients and consequences aggressively, to recognize lever of

to emphasize proteinuria importance goal, function. the treating preserve guidelines and the on rapid of to reductions reinforcing kidney to patient's continue We to the of kidney sustained and

Over driving decile LUPKYNIS of in current increased physicians helping quarter, their we new well goal prescribers. home the expanded our we third of preservation. ultimate of as of customers total base high depth kidney the as in of on urgency, of targets, prescribing and our number message activity benefits maintained the goals treatment In the call quarter, therapy the meet of the

starting back Additionally, come therapy see to patients restarts. we're to as

exposure examine is the for it physicians brand. One, and It first an good restarting We a good growing for with bodes of also this with the two, LUPKYNIS; must to a therapy. We LUPKYNIS they're segment are have further experience brand was with they becomes We well unique during have believe begun indicator had patients. therapy, believe because to this comfortable phenomenon. if a opportunity their at They to aggressively, patients, proteinuria messaging and routinely further reinforce discuss patients maintain target X manageable from well need proteinuria levels treat treat the therapy to educational biopsy to data the as study, our levels throughout years. extending these EULAR to EULAR. The on screen the to extension to lupus the of as and guidelines in based AURORA recently support duration both published guidelines efforts. somewhat

LN. and bit treatment published EULAR level, X a to benefit detail areas their advancement LUPKYNIS. recently a regarding little Let me more the for approach into guidelines high At key go the

first to well strict first diagnosis aiming life. The adherence organ diagnosis. LN, routine prognosis regular at damage monitoring earlier with and for to Early clinical of should flares in activity for thereafter. and therapy using SLE screening evaluation organ namely improving The years involvement, of of and as LN, in disease is of remission especially organ monitoring with as assessed need essential is at enhancing and involvement validated preventing disease instruments. driving for each an treatment new quality damage involvement, second. the initiation from kidney and visit patients' especially be organ Vigilant organ prompt is the

that of the the early treatment. therapy. novel LUPKYNIS, maintenance move recognized combination in LN The committee of for long-term therapies." "With will up paradigm breakthrough treatment And use CNI of the the induction third in shifting need LUPKYNIS regimen line shift is lastly, consider that for a a to

physician's LUPKYNIS, years the of X treatment treatment X LN study, years of upon continue these extension should throughout at believe LUPKYNIS long-term management eGFR to with least the for in actively response and the AURORA approach stable data. We LN regimen. based support to renal leading the strategic Following how guidelines use that reported our of

and screened educating their for they We themselves. second them their kidney condition are lupus to monitored patients to that they are involvement the that on advocate for and routinely their of to ensure is well-being kidney preservation. focus seriousness ensure appropriate need with and getting Our

and We screened. They about by that the manner. of social The run reach cost-effective on in the not through consequences their have these monitoring channels target to and also majority a getting of media routine audiences educating marketing focused ongoing disease to campaigns patient-directed several patient advocate digital physicians. campaigns the are maximize for their

of We Braxton, and reached of for disease have media also been has lupus our campaign her uncomfortable. To impressions spokesperson million thousands get XXX SLE unbranded working over Tony tens with the awareness patients. nephritis and date, message

data our Rheumatology, LUPKYNIS. great the data efficacy company official therapies is launch a of In remainder the was the publication the September, towards establish extension Arthritis recently for a all clinically biopsy foundational into go strategy long-term differentiating & data LUPKYNIS to the third reinforcing gives with directed therapy the extension X of working AURORA the journal ACR. This published to year as for The in substandard patients. LUPKYNIS. safety us along the Our and opportunity of from LUPKYNIS of and LN announced

LN ongoing and are treatment In on LUPKYNIS. affairs evolving the initiatives care focused health addition, approach our medical educating professionals about for

that XXX XXX continue development. leaders work They that of latest with to the support the medical global in medical the guidelines as the well medical guidelines and KDIGO under as follow-ups over to continued guideline ACR engaged upcoming to efforts. This light visits. and LN they for related clinical presentations, true over data times. their EULAR teams care our information requests providers X,XXX quarter, third XX holds health ensure with key Throughout the physicians and and recent information opinion have Our team are writing engaged

November, posters the X Rheumatology they in presented. being upcoming of American meetings in of for and Society accepted have medical abstracts the Nephrology (ACR) that XX For and College the were (ASN) American major

moving to for Now globalization our efforts on LUPKYNIS.

with securing approvals X the of various major in million Otsuka this authorizations, Commission, in Having launches year. European and momentum pricing now U.S. launch significant outside securing recognized on Otsuka third quarter, $XX for we and received in pricing in marketing and countries Our from the milestone reimbursement X approval resulted focused the British Swiss is throughout and collaboration a countries has Europe. In Otsuka reimbursement Europe.

In we LUPKYNIS. quarter, addition, related fees plant portion of as offsetting on royalties and our collaboration revenues fixed started mono sales a well this our our recognizing facility to for as European

remains the launched. eligible for additional work track currently approval XXXX, around Our regulatory on a be anticipated royalties million with the we on of Japan half is end year. Upon Japan, for submission in second in would which low double-digit before approval with the milestone Japan, in net the once of for an $XX Otsuka along sales

close R&D with me let Now activity. our

enroll We of in vocal patients XXX activated remains The we also sites and patients enrolled. continue our currently, with and ongoing. screened LN pediatric total have study registry, to XXX a XX

track pipeline, the our an our for As by remain BAFF/APRIL IND end inhibitor file for on AURXXX, the of to year. we

a autoimmune potential high asset. with and to indications We unmet evaluate medical this need kidney-related continue for target

macrophages receptor, towards product an IND As in we this reformulation peptide XXXX. for as are work novel submission of MX that via our by currently this we modulates therapeutic on AURXXX, end work the anti-CDXXX

over Joe, a turn call announced I I'd ongoing which strategic you on update few to a to months Before brief review, the give the we like back.

at we a the of reminder, review initiated June. of a strategic company the As end

to potential of work options possibilities, which reviewing the ranging strategic process of variety from through for include sale, strategic merger the continue We other company, transaction. a a or

reflects that the our you we time, the with it turn now other a might stakeholders, process all the these a to And over our questions and best and including patience of for our any to have I'd patients, then ongoing. updates is for key detailed material the remain matter. at the financial health like to interest to something will I employees. We will the that, running further in share of more call process committed when up than at our for and shareholders return the know to Joe of that matters that company, the actively our review fulsome results. have. stakeholders. open have we care a of ask the line of quick end for We providers and We on Other appropriate recap share no Joe? call your course,

morning, Thank good you, Peter, and everyone.

obligations in working mono cash, sales and $XXX.X we As supporting XX, resources funding at few operations, QX have at infrastructure, of restricted XXXX. cash manufacturing XX, plan million of of million advancing of funding commitments, and September our $XXX.X $XXX.X cash we primarily FDA-related cash at is equivalents, payments, commercial our least to cash, drug, fund post-approval commercial investment post-approval had cash capital next partially million decrease sufficient XXXX, the related supply, in equivalents, of pipeline activities, our investments offset and The cash to drug programs our and to XXXX, compared including in the December of commercialization and an from and approved purchases, increase end advancement packaging our continued of research inventory commitments financial investments the restricted LUPKYNIS. We and years. activities that development our funding by which for and believe commercial our receipts include LUPKYNIS,

million the XXXX, collaboration revenue of the in September quarter Now revenue ended was as XXXX, partially to a minutes XXXX, September and quarter XX, the well third the and go into XXXX. XXXX change X months the million XXXX. aforementioned for quarter X milestone-related increase for revenues. Total ended following year few Otsuka for XX, for sales product offset ended $XXX.X and of our from months ended and for EC $XX.X revenue additional financial let's September product marketing results ended the for due quarter $XX.X months the September ended months a cost million LUPKYNIS detail XX, XXXX, the and September Total XX, market. Total the XXXX. in for to increase is offset operating product of ended XX, for to The in milestone to for increase $XX.X authorization the quarter primarily reimbursement Net driven the $XX.X the was and decrease million periods of and regarding months XX, recognition partially the the net and pricing was in of ended our operating million net ended XXXX. The September quarter take of $XXX.X was revenue ended XX, due regulatory predominantly million XXXX. XXXX, the main in by $XXX.X for million and million months sales net is expenses due million period. for in million revenue X million XXXX. The from the product the by XX, September by million $XX September as was period-over-period X $XX.X versus the LN and sales XX, XXXX, increase LUPKYNIS, X recognition the an quarter Otsuka further $XX XXXX, penetration customers was September in $XX.X net $XX.X XX, million for XX, both cost revenue, $XXX.X expenses X September X September ended the a XXXX. Total The for is ended prior XX, $XXX December September million milestone

was finance versus June the and of inclusive a and monoplant $X.X the $XX.X XX, now LUPKYNIS a was SG&A during XX% fees were professional the increase due administration ended for was costs months the period. of right-of-use with study ended months year XXXX, of for million million respect a including ended $XXX.X primarily months in share-based the was September XX, was increased million and me XX, in $X.X to on of X versus XXXX, increase is September decrease XX, quarter XX, driver prior and associated fees an by its study, XXXX company with monoplant the both the that for operating which drug-to-drug its for XXXX. The costs for ended insurance, and expense compensation million period. XX, for XX, the for the of increase X to compensation was rates. ended right-of-use costs, of were services, Noncash was September was in X inclusive expense of amounted was an compensation partially $XX.X compensation to a ended to quarters September The decrease versus compensation expense in included XXXX. of CRO expense XX, were respectively. The prior an September $XX.X XX, write-down The assets services, XXXX, finance in XXXX, of ended ended due million with compensation, for in of in primary expense, driver the XXXX. Gross for XX% for batches. and at September and both expense reserves the $X XX, $XX XXXX. as $X.X months million and included expense at cost legal primarily The XXXX, give in within the XX, XX, quarter yields September at an million million million of in partially million expenses million for million share-based validation margins compensation offset AURORA result The as inventory and $X.X million XXXX amortization September of sales in months months million coupled the breakdown period primarily continuation included XXXX. to compensation. SG&A September R&D XXXX, general $XXX.X the decrease decrease partially during XXXX, primary drivers XX, at and the the X for $XX.X this and $X.X versus September September months versus the development, in completion R&D months XXXX. XX, inclusive an X September XXXX. share-based the you was expense offset XX, for the fluctuations. XXXX. Interest XX, million XX, XXXX, advances in and SG&A inclusive million the margins FDA Interest coupled Let XX, fees and September R&D Selling, XXXX, sales XX, XX% was September for for expense. Noncash expense sales $X.X XX, compensation $XX by due compensation to the XX, months X XXXX, by assets. of the due $X.X amortization an XXXX. asset, ended in litigation to expense by was interest LUPKYNIS million million of due prior other professional to September XX, the share-based expenses incurred the sales offset X ended the Noncash for September increased September the for X with September primary Gross due $XX.X on quarters X rent and is expenses, was Cost placed in XX, within higher the drivers XX, was September million our advance ended for respectively. September with September quarter decrease increase of share-based legal respectively. million substantially interaction share-based share-based higher an $X.X $X.X were and year was expense quarters September at XXXX, increased million fees and the ended XX, included $X.X $XX.X quarters increase partially including for and The ended into September compensation ended development increase increase share-based XXXX, and Noncash million year $X.X income versus income share-based million for matters XX% to pipeline increase XXXX, with XXXX, preclinical the corporate and increase for and periods XX, versus including service the September R&D ended September occurred million expense late $X.X increase XXXX, quarters the the $XX.X offset Cost X-month expense SG&A further which asset, share-based share-based completed and XXXX. is September investment period. Research XXXX, XXXX,

XXXX, loss quarter compared Aurinia the per XX, a loss September $XX.X loss as to common September ended net $X recorded per for $X.XX or XXXX. net XX, share million common loss quarters the or net million of For ended of a share net $X.XX

For back to per or $XX.X or share common common XX, XXXX, X $X.XX the to million ended X for $XX.X over loss net that, million share remarks. compared ended Aurinia XX, Peter? of for some September net net $X.XX a as the recorded September the months to loss a of loss months I'd With loss closing net Peter like XXXX. hand per call

Joe. Thanks,

throughout call, about obviously first the year. heard X excited As we're you quarters quarter the the our through for momentum our and results of strong the

We focus fundamentals execution. business continue commercial on to and

the delivering Our study and on concentrated newly extension on of their care are published patients. data providers promise health the kidney nephritis from lupus for prevention educating the AURORA commercial X teams

are teams value And We to patients ask want all to LUPKYNIS focused and globally. I'd now way. along you U.S. working of on the look joining review delivering for the Board us posted are I there And remain team key to R&D results you all may operator into in forward and open be. Operator? behind molecules for to and our for in need on all any our markets our and today. the advancing lines questions X driving scenes keeping in the strategic process on stakeholders the our thank day-to-day clinic. deliver We the to LUPKYNIS regulatory commitments Aurinia. executive Our to pipeline our focused business

Instructions]. [Operator

with Jefferies. is Maury question first from Our Raycroft

and stabilizing Farzin on at to XX see It's for months. good persistence far months is This the Maury. so XX

to leverage the from for guidelines feedback can you patients? So And are the you prescribers further educate. the how getting talk much about you're more doing those

we're after not as the the only you XX of and XX listen, by months Yes. encouraging. curve the XX it on Yes, to a call, I XX-month of shows the but thank we report persistency kind persistency, which question. months, is XX-month mean encouraged didn't flattening for

all think in X-year was period had the with driven the data, should most continue be be safety and launched efficacy presented the so which product where of AURORA the a in original that medical promote channels year I right key requests our was the of to which was and X there X medical through years meetings through and of data. affairs And to to information one ASN that data extension time actively through now. And top to at on go presented publication recently head and since and recently additional has biopsy to added X on of period ACR the out and a AURORA which data, way years right regional are physicians. adding providing approval study, data, and the will at we the of ability takeaway time the come data of this an got has the with

we're obviously, of results the by start-and-stop negative see it. the guidelines the be and remove ASN, maintaining we and from quite actually or MMF patients. would that of reducing new reinforcement ACR we're patients encouraged coming and on guidelines published future this process includes therapy a because, times, already of importance been and -- So control for proteinuria, historically, a of keeping that Feedback many meds, disease of encouraged inflammatory and steroids. The patients physicians get will sort that from has and is show physicians a patients we

a encouraged and shift the there's data. So we're by happening

feedback So the gotten we've has been far good. so

they increased yet? your on efforts rates based far, to a leading of have then so you And are do diagnosis whether sense

what this you at to qualitative important quantitative but I forward only qualitative on look is have we reporting we not yes, is for the the the front. as market growth, future tell of is but All total. of the brand, And point in would data that it's more

data, encouraging qualitative yet. nothing but So quantified

Joe, And then quickly quarters. significantly higher prior scheme for is versus COGS the

that. If some you on color can provide

the online tail the prior quarter. monoplant came the of mentioned second Yes. right call, in the Farzin, as at quarter end

facility, the actually reflected collaboration So third portion, is of full under a Otsuka is approximately the which quarter, supply in the this we a quarter, absorption of had via plant reimbursed mono XX%, revenue. agreement, which

So an you little bit see revenue. reflected a offset the collaboration in of

question with is Joseph Leerink next Schwartz Our Partners. from

all, higher quarter. and wondering, looks even not will to like was first of if arrived patient start at what low the you hit It you be why the proportionately if numbers third might to could robust seen you decrease about fourth especially from this given you how a your I guidance end October. the the able delivered talk it be sales we've quarter, for bit to forms new

So I'm just your wondering have any that? if follow-up. pensiveness I into And us there's you can insight reason give for or a if then

Yes.

is of the short answer we expected low We raised because Joe. question, the The right. end the guidance I you're think

We've new to upon patient that guidance. to and range range. to conservative low of based the somewhat tightened the we going we wanted the that in fall actually about we the saw get decline where starts quarter, because end have the to think be you'd to even I in quarter were

in saw we still we QX, So starts conservatively that range. can patient of guidance feel if for we sort same that hit new example, the

new would have upper we of of consistent that a be QX, patient end be higher doubt off below, to that wanted be If the think performance. there's there the decline you number in no And below starts we fell with and taken guidance you'd that level have I quarter we just to of to range. predictable range. in our a seen Had conservatism there's

just but and latter insight prescribers trending helpful. of be numbers, you the each of the has breadth any into to prescribers total on relative are prescribers wondering LUPKYNIS within practice. the how relative We for the penetration I'm then appreciate the been And number to LUPKYNIS the repeat number how former satisfied would drug? with of patients

Yes.

you yet, go chew we about it's but numbers reporting. the for as back one think haven't know, prescriber us to Joe, total think I given and on and

utilized the in Some thousands what base. is can from physicians our both I prescribers we've product of tell increases within have and total our repeat reasons. of now of on there seen that competitive you of percentages double-digit that been volume prescribing that terms in for that's prescriber are But universe and

So happy with we're the penetration.

that all along the here, the of we continues is of our treatment there and good, universe and somewhere the XX% to and applies prescribing our penetration prescribe nephrologists of prescribers. the of that said think XX-XX from depth quite prescriptions rheumatologists XX% we've actually come of of around LN, And As improve. within for lupus rule products the universe and

on reporting that's numbers. future specific calls, out. get more to rolled competitive start we the As reasons But we for to as look as we'll we haven't that want I into whether why said,

Stacy Our Ku next from question TD Cowen. with is

and very is Joe, Vish on strong of quarter. on line the Peter congrats Stacy. a This

we it, talk patient your over How bit about you XXXX? So you X for year? sales results behind start have and a see expectations given do more little out next quarters could forms from panning

stay have around last next Yes, steer with to things that's response year. to or And mean that, last to think of consistent JPMorgan fast prior I of a did that. we're what I before or but sort we lot I some to on a try what and going year. give did there's we year weighing

it the characterization QX XXXX. on I think we And JPMorgan. that or to we in saw some we gave tighter to due then summer got in reaffirmed challenges prior

and So that we're XXXX for going to stay until with then. consistent look give any not

You question, had [ another Vish? ]

the regarding net question a pricing. had I Yes.

you seems on even that call, we're the on over settling that for little a price. QX the price see release that seeing above bit the in is net it press do How guided the QX? based the information So given and

look net so not continue much year. guess, is closer patient and closer downward I dogmatic we encourage way will But, realize slowly of I I it can that settles $XX,XXX I helpful just give sailed But pretty to hope think the estimate quarter, be going closer the think I per trend patient think year. to as that average it our to the would be appreciate out, We of per think to there. guidance, that would very to an we per at that what average and I quarterly then net about XX this trend to about have point. and into do per you of best -- been everyone we've and down don't

next Our Olivia Fitzgerald. is Brayer question Cantor with from

in to It September. there's looks trends. PSF a and drill wanted downward versus what you in trend I like down October August on saw

thinking start the we then few for I a quick got should So over be And patient follow-up. how growth months? about next

October first same thing historically still years take the it that. Well, Yes. than we is X those the had had in seen that backwards trend in I what year. higher period we summer to little would see that was it PSF did in before just encouraging then we not seen work bit time was a And the months the last the on

And I in So, leave look into too with. you will is read lead we months around saw And saw guess, numbers summer I I it. much is in recent to difference to with we're we're October. PSF somewhere to what not talking those trying what XX would encouraging from all X we what

would now hope our October, consistency level December, a of And November, trend, an in that So I'd that to there. we into going say get be, increase see so. we're as there's

any learnings color you the June? really, there any any question whether been how the color process from on it have since is you or I And give us And going? more strategic is or review began my takeaways back guess, Yes. can in process

you on here. say can't are somewhat tied and what As I I'm can sure appreciate can hands my

the and very our to that directions, at very we've and in to do material done much We So real gives and in it. see outside this I'm to of it's strategy all a we're report, more to level to serious, I report Board can't more but taking our open do something hard. opportunity the saying sure keep way that, that going we that When historically so. outside focused have or out, us color. obviously working best that's it of make a and mind that, an not to we're we'll not this both But to stick level. give interest And accelerate management that as

Justin Our next from with question & Oppenheimer Company. is Kim

maybe Have seen sort be that that being be any new smoothing a might and there's sort is of reached more of helpful. you I base maybe do would level whether this color you Just or that as what of certification any the curious, have a color question kind script just of and driving touch Just wanted additional here? to to more seasonality practice prescriber again. on summer? smoothing maybe of avoiding

you. hope I Justin, Philadelphia well for going is

our people well day-to-day Our work which and the months people as give credit on ground are team in on is marketing worked I basis. lot of I out and this, driving the different to that sales is for ASN. who doing their there a We the angles. think summer a And

published think the We helpful. quite is study around data biopsy bit tactical a execution data extension I quite period. during that helpful. The time of had being was the

to levers. points I think all potential

product to that your to just out start the I the It's execution, the, and it's but importantly, big levels that it base the future. long-term trends. continue how near-term and and can of consistent new prove think PSF to can reaching question growth pull more need going forward that for one we're important the on and is the we not the be in that

guidelines, what of new different see underlying yes, all to I that. XXX have is, call are we bear that PSF it, that, and or things let's of And be reached impacted our XXX and those are new guess, we host continue point to new target tactics And push and reinforce components outside of see unleashing PSFs -- market, need need on start to a I disease, to. treating talking terms that then, and X to parts about we is plateau of believe quarter question XXX the your well, to moving alongside beyond. the the XXX key from So which to bring per so of data performance, this a on data in to we would of to

with question Ed Wainwright. next Our H.C. is from Arce

ACR, show LUPKYNIS. seems scripts from as supportive guess, as DDI on the points that, X ones need expect patients. driving ACR would for I X about have more the with the ask as an components believe growing a the are? guidelines visited nephritis. or And would consistent of for as that We include approach study? Obviously, novel how to day, And, I along is But us. important therapies when many EULAR to potentially the is, and was group with SLE published for wanted with getting approaches. I doing And consistent treatment there from new they'll forthcoming, our they see you of there you really and reinforce today, patient going urine KDIGO several think as major to do Peter, And visit mentioned, we're been KDIGO within add to guidelines novel use have some to the pipelines starting being line consistency, back I are diagnosed. view I get office as any emerging me The guidelines. every quite important patients have of to predicting well newly address in space quarter, aggressive they wanted to there'll therapies on these greetings other prior consistently? and you companies you although be old patients for really address studies go, predict in diagnosis that productivity let guess the in the their will lupus given that diagnosed congrats currently But I'm think can't hopeful ASN. do as driver to you only that can't somewhat aren't an EULAR more guidelines SLE these be as as for about physicians from guidelines, a existing a they office that which that and that practice will be always to SLE work. but I time Joe, just novel there where you the ask, awareness screened. We and supportive my rewind One where XX% the as therapies. I strong the be guidelines guidelines, it huge of with EULAR things to well EULAR, screen mentioned are and and you're that

don't a trying months and aligned X is levels to. we're actually levels data, and treating the that and those proteinuria today, performance aligned shows treat second at know nephrologists by the aggressively to The and months And certain product only with to our to target X guidelines. that target consistent year reach we levels rheumatologists

more start to and So see I market that the we fashion, there physicians within we congruent is can guidelines grow. a can get gems lot if of a treating, in just guess, the actually

for. published. whether what of biopsies has published been been study or when the published The We'll extension And We're guidelines. they Published these actually they'll now and question the new data last that's data get look working is form. data, an they been Your incorporate the The too. hard AURORA data. usually not published. see stuff point But to poster biopsy abstract usually, study poster. published they at has

question. for the length the of Sorry

RBC from Markets. Dhingra Our next is question Capital with Sahil

prepared remarks Dhingra I is this that have Miehm. in Sahil is comment made questions. My quarter. first for higher the the This X there Doug on discontinuation question were some

to the how on it on it Or have more been the degree? to summer dependent seasonality for long drug? a related So is is patients

It's the latter.

have to a dynamic as for this quarter. see for the we average more rationale in quarter, have why think obviously, on during months in a you think had been dynamic discontinuation it have model the periods rate about it, mix as longer to about some fashion. X you in therapy -- And can who patients And, you're tell a a drug them saw was on the patients months, that patients higher of versus There's quarter, think of seen a who patients just it XX for question? who've if Do to you more I in rates. of another you we this discontinuation for time. see been drug higher going no

the this related know is before, color. provide to you was Yes. And second more could asked prescribers, I my if question but

had in How the of on trend new you are not that we the one data that has repeat prescribers. calls, think have I earlier hand? XX% mentioned changed prescribers the of given that

than more or and prescribing tries. now tries XX% dependence a percentage having initial higher see improvement than upon The short a board, answer seen higher less across is the patients first-time we've we

we So this. I as data -- because a haven't of we the said, on we quant this segment do -- reason lot pretty

one, And best fronts competitive least the that lot a I we of depth at that to prescribers, meaningful little think, number give in during haven't out the it's at But is whether data. to of our/or on and I out we've set think a made terms tell both of our closer total quarter. We you rolled important, stage, primarily we because this of can this movement there. that's prescription keep

Our question Burton. is next with Bloom from Martin David

one data? more changed progress the nephrotoxicity based label is or the affected asked. I'd And the any they'll extension getting the be think U.S. crafted, AURORA follow-up you you U.S. first question on by language? guidelines on the language made EULAR when language type to and in biopsy by the that the a label The Have the are in do

data heard we agency. be the not land call will back agency Well, meaningful this but I that U.S. the the in the that the announced this had the substudy I data here label predict extension where at June We're this can't incorporated was U.S., hopeful can a and we as is we've going into the to in everyone is predict stage. go, on. but we biopsy were where way the study agency anything can't both from the agency to And expected extension and that the FDA. going on from to expected to reinforce submitted data in It

label think much by swayed do the you And the or guidelines are not? that

No.

it's published think a I data.

new Second restarts question, do the PSFs? require

require restart No. PSFs? new The

European did countries got And last you the question, pricing? you what get the in pricing where

of We sort can't and domain. specifically [indiscernible] every country a for speak it's

the this as pricing be novel to color terms not pricing give want or the getting appropriate of reference something would I of in just in see Benlysta, be generic negative it that in trolmus But they much I'm can we the sure that. terms would outcome So like you disclose. therapies pricing, a set like of how like

very again In time, your I look much, want talking and to the to you that all for we and all forward have Thank thank day. you you have great that's to fears today. next we quarter. for questions a

Thank will conference. This conclude today's you.

participation. your disconnect may thank lines for you You time, this your at and